Olga M. Gordeeva

Olga M. Gordeeva

Auto-generated profile, based on publicly available information

Olga M. Gordeeva

Central Tuberculosis Research Institute

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
OGO M Gordeeva
O M Gordeeva
AEA D Egorova
A D Egorova
YCY O Chesalina
Y O Chesalina
EGE M Gretcov
E M Gretcov
LSL A Semenova
L A Semenova
ISI V Sivokozov
I V Sivokozov
In December 2018 the patient over 60 years old sought medical help with complaints of persistent cough. Based on computed tomography data there were identified the sings (symptoms) of right lung lower lobe atelectasis. To run this patient diagnostics there were performed 6 bronchoscopies narrowed down by bronchi checks up only and described the right lung central cancer picture. At the same time the biopsy taken during one of the bronchoscopies appeared non informative. Fine needle biopsy of mediastinal lymph nodes and bronchial wall was performed twice: at Tomsk Cancer Research Institute (it was suspected B-cell lymphoma based on biopsy examination) and at The Loginov Moscow Clinical Scientific Center (signs of inflammation based on biopsy examination). The video-assisted thoracoscopy with lymph node dissection of the right lung root was performed in January 2020. As a surgical material analysis result reactive adenopathy was determined. Therefore, during more than 1 year of diagnostic research the genesis of right lung lower lobe atelectasis was not established. The patient was directed to Central Tuberculosis Research Institute for diagnosis verification. Based on clinical and radiological picture Central Tuberculosis Research Institute colleagues suspected a foreign body in the intermediate bronchus. During an endoscopic examination it was revealed stenosis, biopsies were performed, but the foreign body could not be identified. In the pathomorphological laboratory of Central Tuberculosis Research Institute there were conducted histological examination of the material after endobronchial cryobiopsy and rigid needle biopsy. Both gave an unexpected result: invasive mycosis of the bronchial wall. As a conclusion the decision was taken to apply antimycotic therapy on an outpatient basis. As a result, clear clinical and radiological positive dynamics was obtained. In these favorable conditions for endoscopic examination, it was performed vitally essential cryoextraction of foreign body. The foreign body turned out to be a fragment of a spongy bone of a centimeter size. These actions have let to unlock the right lung lower lobe.

1 October 2017 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
NKN. L. Karpina
N. L. Karpina
CFCentral Tuberculosis Research Institute Russian Federation
Central Tuberculosis Research Institute Russian Federation
OGO. M. Gordeeva
O. M. Gordeeva
TNT. S. Nabokova
T. S. Nabokova
ISI. Yu. Shabalina
I. Yu. Shabalina
AFAcademician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs Russian Federation
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs Russian Federation
Заболеваемость туберкулезом среди лиц, ожидающих трансплантацию почки или живущих с трансплантированной почкой, превышает таковую в общей популяции в десятки раз, что связано с формированием медикаментозного иммунодефицита. Пока не существует единого подхода к лечению туберкулеза у таких пациентов, так как следует учитывать многие факторы: лекарственную устойчивость возбудителя, взаимодействие противотуберкулезных и иммуносупрессивных препаратов, развитие нежелательных побочных реакций и токсическое воздействие на почку. Приводится клинический случай диагностики и успешного лечения туберкулеза легких, внутригрудных лимфатических узлов и бронхов у пациента с хронической болезнью почек в терминальной стадии после трансплантации почки.

1 January 2020 in Nephrology and Dialysis
Verified
Journal Article
Closed access
FIFederal State Budgetary Scientific Institution
Federal State Budgetary Scientific Institution
OGO.M. Gordeeva
O.M. Gordeeva
CICentral TB Research Institute"
Central TB Research Institute"
NKN.L. Karpina
N.L. Karpina
FIFederal State Budgetary Scientific Institution "Central TB Research Institute"
Federal State Budgetary Scientific Institution "Central TB Research Institute"
ELE.E. Larionova
E.E. Larionova

7 September 2020 in European Respiratory Journal
Verified
Conference Paper
Closed access
OGOlga Gordeeva
Olga Gordeeva
VHVladislav Hergert
Vladislav Hergert
ILIrina Lyadova
Irina Lyadova
NKNatalya Karpina
Natalya Karpina
Introduction: In patients with end-stage kidney disease (ESKD), the diagnosis of tuberculosis is extremely difficult due to the lack of a classical clinical and radiological picture of the tuberculosis process, oligobacillarity and anergy of tuberculin skin tests (TST). Now, studies of the efficiency of the quantiferon test among immunocompromised populations are being conducted worldwide, but there is very little information about efficiency of this test in patients with ESKD. Aim of study. To study the value of the quantiferon test in the complex diagnosis of respiratory tuberculosis in patients with ESKD. Materials and Methods: Immunological studies (quantiferon test and tuberculin skin test) were performed in 23 pts. with ESKD who applied to the Central TB Research Institute to clarify the diagnosis since 2010 until 2019. Changes in the lungs and/or fever in these pts. were revealed for the first time. Results: According to the results of the survey in 10 out of 23 ESKD pts. (43.5%) the diagnosis of active respiratory TB was verified. Other active respiratory diseases were diagnosed in 13/23 pts. (56.5%). Skin test showed a lower sensitivity (60%) compared to the QuantiFERON®-TB Gold Plus test (70%), while both tests were highly specific (100%) in the detection of TB in ESKD pts. For all indicators, statistical significance was determined (p <0.05). The agreement coefficient (Kappa) of the QuantiFERON®-TB Gold Plus test results with the skin test results was 0.671. Conclusions. Given the high specificity (100%) and sensitivity (70%), it is possible to consider the use of the QuantiFERON®-TB Gold Plus test as an additional method for the diagnosis of tuberculosis in ESKD pts

28 September 2019 in European Respiratory Journal
Verified
Conference Paper
Closed access
OGOlga Gordeeva
Olga Gordeeva
MTMaxim Telepnev
Maxim Telepnev
INIrina Nikitina
Irina Nikitina
ISIrina Shabalina
Irina Shabalina
LCLarisa Chernousova
Larisa Chernousova
ILIrina Lyadova
Irina Lyadova
Introduction: There is lack of data about the value of immunological methods in the diagnostics of TB in chronic renal failure (CRF) patients in the terminal stage, who are immunocompromised due to replacement therapy or kidney transplantation. Aim: To evaluate the value of immunological methods for TB diagnosis in CRF patients. Material and Methods: 34 CRF patients were included in the study (18 (53%) patients diagnosed for TB, 16 (47%) – for other diseases). Immunological analysis included: tuberculosis skin tests; QuantiFERON®-TB Gold Plus; T-SPOT®; the determination of Mtb-specific CD27-IFN-γ+ cells (“Mtb-CD27”), the evaluation of CD4+, CD8+, CD19+, CD16/CD56+ cells. Results: IGRAs showed low sensitivity (47%), but high specificity (93 and 94 %) and demonstrated higher concordance with the diagnosis (~70%) than skin tests (64%). Mtb-CD27 had high sensitivity (82%), but low specificity (13%). The latter was likely due to bystander stimulation of CD4+ lymphocytes in CRF patients leading to a high percentage of CD27- lymphocytes within CD4+ population. Flow cytometry analysis demonstrated lower counts of Mtb-specific IFN-γ-producing CD4 lymphocytes in TB patients with CRF compared to TB patients without CRF, which could account for low sensitivity of IGRAs. Conclusions: Immunological tests can be used in complex diagnostics of TB in patients with terminal stage of CRF, but their limitations should be taken into account. Low sensitivity of IGRAs can be explained by insufficient counts of Mtb-specific IFN-γ-producingCD4 lymphocytes. Low specificity of the Mtb-CD27 can be attributed to pronounced inflammation associated with CRF

13 July 2022 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
OGO. M. Gordeeva
O. M. Gordeeva
ATA. M. Tikhonov
A. M. Tikhonov
SAS. N. Andreevskaya
S. N. Andreevskaya
ELE. E. Larionova
E. E. Larionova
NKN. L. Karpina
N. L. Karpina
Цель исследования: определить возможность назначения и безопасность применения различных противотуберкулезных препаратов и их комбинаций в рамках терапевтического или профилактического курса противотуберкулезной терапии (ПТТ) у больных в терминальной стадии хронической болезни почек (ТХБП), получающих заместительную терапию гемодиализом в условиях высокой распространенности штаммов микобактерий туберкулеза (МБТ) с лекарственной устойчивостью. Материалы и методы. Под наблюдением в ФГБНУ «ЦНИИТ» находилось 42 больных, получающих заместительную терапию гемодиализом: с активным туберкулезом – 31 (73,8%) чел., с остаточными посттуберкулезными изменениями органов дыхания – 11 (26,2%) чел. За период наблюдения проведена оценка характера и степени тяжести нежелательных реакций на противотуберкулезные препараты. Результаты. У больных ТХБП с туберкулезом органов дыхания преобладают лекарственно-устойчивые штаммы возбудителя – 68,2%. Среди нежелательных явлений при приеме противотуберкулезных препаратов встречались: нарастание явлений уремии ‒ в 20,5% наблюдений, сердечно-сосудистые осложнения – в 17,9% и нейротоксические реакции – в 15,4%. Нарастание уремии при приеме противотуберкулезных препаратов у наблюдаемых больных встречалось достоверно чаще, чем гепатотоксические реакции (p = 0,02). При лечении туберкулеза у больных ТХБП из-за нежелательных явлений требовалась отмена изониазида в 12,8% наблюдений и пиразинамида в 12,8% наблюдений, другие препараты реже. Индивидуализированный подбор ПТТ с учетом данных теста лекарственной чувствительности МБТ, противопоказаний, сопутствующих заболеваний позволил подобрать адекватную ПТТ больным ТХБП с туберкулезной инфекцией в 92,9% на срок более 6 мес.